| Item Type | Name |
|
Concept
|
Antiretroviral Therapy, Highly Active
|
|
Academic Article
|
T cell responses to recall antigens, alloantigen, and mitogen of HIV-infected patients receiving long-term combined antiretroviral therapy.
|
|
Academic Article
|
Characterization of quantitative and functional innate immune parameters in HIV-1-infected Colombian children receiving stable highly active antiretroviral therapy.
|
|
Academic Article
|
Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir.
|
|
Academic Article
|
Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Women's Interagency HIV study.
|
|
Academic Article
|
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.
|
|
Academic Article
|
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.
|
|
Academic Article
|
A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment.
|
|
Academic Article
|
Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function.
|
|
Academic Article
|
Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.
|
|
Academic Article
|
Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype.
|
|
Academic Article
|
HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients.
|
|
Academic Article
|
Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine.
|
|
Academic Article
|
Normalization of immune activation in lymphoid tissue following highly active antiretroviral therapy.
|
|
Academic Article
|
Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.
|
|
Academic Article
|
CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies.
|
|
Academic Article
|
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
|
|
Academic Article
|
Recent observations on HIV type-1 infection in the genital tract of men and women.
|
|
Academic Article
|
PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes.
|
|
Academic Article
|
GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy.
|
|
Academic Article
|
Early immune senescence in HIV disease.
|
|
Academic Article
|
CCR5 and CXCR4 expression after highly active antiretroviral therapy (HAART).
|
|
Academic Article
|
Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery.
|
|
Academic Article
|
Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease.
|
|
Academic Article
|
Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group.
|
|
Academic Article
|
Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study.
|
|
Academic Article
|
Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181.
|
|
Academic Article
|
Microbial translocation is a cause of systemic immune activation in chronic HIV infection.
|
|
Academic Article
|
Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.
|
|
Academic Article
|
Characterization of CD4? T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients.
|
|
Academic Article
|
Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection.
|
|
Academic Article
|
HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course.
|
|
Academic Article
|
Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s.
|
|
Academic Article
|
Impact of Hepatitis C Virus on the Circulating Levels of IL-7 in HIV-1 Coinfected Women.
|
|
Academic Article
|
Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286.
|
|
Academic Article
|
HIV infection and aging of the innate immune system.
|
|
Academic Article
|
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2.
|
|
Academic Article
|
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4? T-cell recovery despite sustained virologic suppression: ACTG A5256.
|
|
Academic Article
|
Neurodegeneration and ageing in the HAART era.
|
|
Academic Article
|
Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.
|
|
Academic Article
|
Towards an HIV cure: a global scientific strategy.
|
|
Academic Article
|
Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV study.
|
|
Academic Article
|
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.
|
|
Academic Article
|
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
|
|
Academic Article
|
Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients.
|
|
Academic Article
|
Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics.
|
|
Academic Article
|
HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy.
|
|
Academic Article
|
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women.
|
|
Academic Article
|
Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART.
|
|
Academic Article
|
A look at HIV immune research. Interview by Alan Huff.
|
|
Academic Article
|
Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy.
|
|
Academic Article
|
Higher Body Mass Index Is Associated With Greater Proportions of Effector CD8+ T Cells Expressing CD57 in Women Living With HIV.
|
|
Academic Article
|
Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy.
|
|
Academic Article
|
Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy.
|
|
Academic Article
|
Loss of CXCR4 on non-classical monocytes in participants of the Women's Interagency HIV Study (WIHS) with subclinical atherosclerosis.
|
|
Academic Article
|
A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.
|
|
Academic Article
|
Vitamin D does not modulate immune-mediated bone loss during ART initiation.
|
|
Academic Article
|
Delayed gastrointestinal-associated lymphoid tissue reconstitution in duodenum compared with rectum in HIV-infected patients initiating antiretroviral therapy.
|
|
Academic Article
|
Sialylation and fucosylation modulate inflammasome-activating eIF2 Signaling and microbial translocation during HIV infection.
|
|
Academic Article
|
Presence of asymptomatic cytomegalovirus and Epstein--Barr virus DNA in blood of persons with HIV starting antiretroviral therapy is associated with non-AIDS clinical events.
|
|
Academic Article
|
HIV and Aging in the Era of ART and COVID-19: Symposium Overview.
|